

## Immunoscore<sup>®</sup><sub>CR</sub> for Immunotherapies at AACR 2019

- Results from immunotherapy based clinical trials including HalioDx's Immunoscore<sup>®</sup><sub>CR</sub> and Immunosign<sup>®</sup>, will be presented at AACR 2019 by biopharma partners
- HalioDx will present 2 posters that will highlight recent technology advancements including the Immunogram utility in CRC and Brightplex IHC staining technology robustness
- HalioDx & Jérôme Galon presentation around “Approaches to treat immune hot, altered and cold tumors with combination immunotherapies” during an affiliate AACR Clinical Research seminar<sup>1</sup> will take place at 6.30pm on April 1<sup>st</sup>, 2019 in Atlanta (Atlanta Marriott Marquis Hotel)
- HalioDx assays are included in 15 ongoing Phase I/II in 7 different indications: Meet HalioDx team at booth #4511 to discuss latest scientific content and assess whether our solutions fit your needs in Immuno-oncology

Marseille, France, March 26, 2019 – HalioDx, an immuno-oncology company pioneering the immunological diagnosis of cancers, today announced its participation to the 2019 American Association for Cancer Research (AACR) Annual Meeting in Atlanta, Georgia (March 29-April 3, 2019), with an **oral presentation and several posters presented by its collaborators and partners**. HalioDx will also be present in **booth #4511** to discuss its diagnostic products and clinical research services. The company will also sponsor an **affiliate AACR Clinical Research seminar on Immunogram on the evening of April 1<sup>st</sup>** in Atlanta that will include a presentation by Jérôme Galon on “Approaches to treat immune hot, altered and cold tumors with combination immunotherapies”. This seminar is open to current and potential partners. If you want to participate, [please register here](#).

In 2019 HalioDx observed a significant increase in the number and diversity of clinical trials using proprietary Immunoscore<sup>®</sup> and Immunosign<sup>®</sup> solutions. Today, HalioDx is involved in 15 Phase I/II trials in immunotherapy, including combinatory approaches and therapeutic vaccines. These trials are conducted in 7 different indications and the results will be made public in the coming years starting in 2020 for some of the clinical studies.

**Vincent FERT, CEO of HalioDx comments:** “AACR 2019 is an important milestone for the company as we demonstrate, with data presented by our partners, that our solutions in immuno-oncology diagnostics bring precious information for patient selection. We are also proud to sponsor an affiliate AACR seminar on Immunogram with Jérôme Galon and partners presenting the added value of our solutions in clinical research.”

### Oral presentation and posters on clinical trials from our partners:

- Early signs of activity of Tedopi OSE2101, a multiple neoepitope vaccine, in a phase 3 trial in advanced lung cancer patients after failure to previous immune checkpoint inhibitors ATALANTE-1  
[See Ose Immunotherapeutics press release](#)

---

<sup>1</sup> This event is not part of the AACR program.

- [CT010 / 5 - A phase I study of the oncolytic peptide LTX-315 generates \*de novo\* T-cell responses and clinical benefit in patients with advanced sarcoma](#)  
**Poster Session:** Session PO.CT01 - Phase I Clinical Trials: Part 1  
**Session Time/Location:** March 31, 2019, 1:00 PM - 5:00 PM | Section 16
- [CT069 / 26 - A Phase I study of the oncolytic peptide LTX-315 generates \*de novo\* T-cell responses and clinical benefit in patients with advanced melanoma](#)  
**Poster Session:** Session PO.CT02 - Phase I Clinical Trials: Part 2  
**Session Time/Location:** April 1, 2019, 8:00 AM - 12:00 PM | Section 17

### Poster presentations on HalioDx technologies by our collaborators:

- [2796 / 12 - Validation of Brightplex, a multiplexed IHC solution for immune cell phenotyping of the tumor microenvironment](#)  
**Poster Session:** Session PO.TB06.06 - Immune Cells in the Tumor Microenvironment 2  
**Session Time/Location:** April 2, 2019, 8:00 AM - 12:00 PM | Section 3
- [4574 / 28 - Combining multimodal biomarkers as an immunogram to guide immunotherapy use: A proof of concept](#)  
**Poster Session:** Session PO.TB06.07 - Immune Cells in the Tumor Microenvironment 3  
**Session Time/Location:** April 3, 2019, 8:00 AM - 12:00 PM | Section 3

### Affiliate AACR Clinical Research seminar on Immunogram by HalioDx

**Location:** Atlanta Marriott Marquis Hotel, room L402 | Time: from 6:30 pm to 9pm

**Presenters:**

Dr Jérôme Galon, Research Director at Inserm, Head of the laboratory of Integrative Cancer Immunology, Paris, : *'Approaches to treat immune hot, altered and cold tumors with combination immunotherapies'*  
Jacques Fieschi, PhD, Senior Director, R&D, HalioDx : *Immunogram proof of concept*

**Registration link:** <https://www.halioldx.com/seminar/>

### About HalioDx

#### The Immune Response to Cancer Diagnostics

HalioDx is an immuno-oncology diagnostic company providing oncologists with first-in-class Immune-based diagnostic products and services to guide cancer care and contribute to precision medicine in the era of immuno-oncology and combination therapies. Immunoscore® proprietary technology, pioneered by Jérôme Galon at the Cordeliers Research Center, Paris, France, integrates immunohistochemistry combined with sophisticated algorithm and advanced imaging analysis enabling extraction of spatially-organized tissue molecular information. Immunoscore® is a platform for many cancers, as immune response to tumor is a key hallmark of disease progression. HalioDx collaborates with renowned international clinical groups to support clinical utility and ensure rigorous performance validation of its assays in selected cancer indications.

HalioDx has an experienced team of more than 135 employees, CLIA-certified laboratories and compliant facilities in Europe and in the US to develop, manufacture, register and market in vitro diagnostic (IVD) products. HalioDx executes biomarker studies and companion diagnostic assay development in conformity with regulations and in partnership with biopharmaceutical companies. The company co-founded the European immunology cluster Marseille Immunopôle (MI).

For more information, please visit our websites [www.haliodx.com](http://www.haliodx.com) and [www.immunoscore-colon.com](http://www.immunoscore-colon.com) and follow the company on Twitter [@HalioDx](https://twitter.com/HalioDx).

## Contacts

### **HalioDx SAS**

#### **Vincent Fert**

President and CEO

+ 33 (0)4 91 29 30 90

[vincent.fert@haliodx.com](mailto:vincent.fert@haliodx.com)

### **ATCG Press**

Marie Puvieux / Solène Moulin (France)

+33 (0)9 81 87 46 72

Céline Voisin (ROW)

Mob: +33 (0)6 62 12 53 39

[haliodx@atcg-partners.com](mailto:haliodx@atcg-partners.com)

[Twitter: twitter.com/haliodx](https://twitter.com/haliodx)